SHANGHAI, Nov 28 (Reuters) - U.S. vaccine maker Moderna began construction of its first facility in China this month to manufacture mRNA medicines, the company said on Tuesday.
Moderna's COVID-19 vaccine has yet to be approved in China, but the company said in July it had signed a deal with the city government of China's financial hub Shanghai to work towards opportunities for it to research, develop and manufacture mRNA medicines in the country.
The facility in Shanghai would manufacture medicines for the domestic population, the world's second largest after India, a spokesperson for Moderna told Reuters.
"Our focus in China is on strengthening health security by targeting unmet needs and contributing to the ecosystem of medical solutions available to patients in China," it said in an emailed statement.
It did not say what it planned to make at the facility and when production might start.
I must be dying. Smh
You re correct, people are dying from Covid because they are not vaccinated, especially if they have a chronic condition.
By the end of 2024, there's a good chance Spikevax won't be Moderna's only source of recurring revenue
Moderna expects an approval decision regarding its RSV vaccine candidate in April of 2024.
Moderna's RSV vaccine candidate, tentatively named mRNA-1354, reduced patients' risk of developing two or more RSV symptoms by 83.7% compared to a placebo. Moderna can argue that results for its candidate are best in class
Today didn't see to reflect that potential dollar figure nor enthusiasm. MRNA has become the worst performing stock in the S&P500 unfortunately for some.
Moderna's potential RSV product could be successful since it would be the only one on the market available in a pre-filled syringe, making it very easy to administer.....
Moderna has also predicted that the 15 planned launches could bring in as much as $30 billion in sales in the coming years. And the company says its current balance sheet is strong enough to fund its plans, so it won't need to raise capital by selling shares.
Light is shining bright
On that which
Has remained hidden
Some things aren't
What they seem
it's sales time....Now$$$$$$ bright future
Brutal year for MRNA longs. Most are probably under water if they went long in the past 2 years.
I still remember that Barron's super positive article on Moderna a few weeks ago. Jeepers, that author sure had terrible timing/opinions.
reported its third-quarter net loss was $3.63 billion, compared to the prior year’s net income of $1.04 billion. The drop in revenue resulted in a loss per share of $9.53, compared to earnings per share of $2.53 a year ago. Additionally, the company decreased product sales forecast from $8 billion to $6 billion.
Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments were $12.8 billion as of September 30, 2023, down from $14.6 billion as of June 30, 2023, driven by the operating loss in the quarter.
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billion
Spikevax U.S. market share to date increased to 45% from 36% in 2022
Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025
Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven by mostly non-cash charges of $3.1 billion related to resizing and a tax valuation allowance
Company's late-stage pipeline has six Phase 3 programs
Company expects to break even in 2026 through product launches and disciplined investment
Research and Development (R&D) and Selling, General and Administrative (SG&A): The Company now expects full-year 2023 expenses of approximately $6.3 billion (previously $6 billion), with approximately $4.8 billion in R&D (previously $4.5 billion).
Moderna's mRNA platform is positioned to continue to deliver significant impact with our mRNA medicines. The Company is anticipating up to 15 launches in the next five years and provided a comprehensive overview of its pipeline and clinical programs at R&D Day in September. Moderna currently has therapeutics in development across four therapeutic areas, with a total of 43 development programs. Other notable updates are provided below.
When life is in repeat
Then it will be
So let's see what happens - Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say
Is everyone immortal
Boils down to
Has nothing to do
With the equation
no one is immortal..$MRNA winner
When delusion becomes reality
Off a cliff
Culling their own
Those few that survive the catapult
Come back and do
The same thing again
Must be something to this
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC “In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy” to be presented Friday, November 3, 2023, at 11:30 am PT
“The data presented at SITC is incredibly exciting as it demonstrates that we have the ability to make CAR-M directly in vivo with mRNA/LNP technology, leading to robust and targeted anti-tumor activity,” said Michael Klichinsky, PharmD, PhD, Co-Founder and Chief Scientific Officer at Carisma. “This off-the-shelf approach to treat cancer with engineered myeloid cells, developed in collaboration with Moderna, has the potential to transform the CAR field and be applied to numerous cancer targets and indications.”
“We are pleased to share data about the successful application of our mRNA platform to advance in vivo cell therapy,” said Lin Guey, PhD, Chief Scientific Officer of External Research Ventures at Moderna. “We look forward to the continuation of our pre-clinical work with Carisma and are optimistic that the joint scientific knowledge of both companies will accelerate the development of novel in vivo CAR-M therapies for patients.”
This is a perfect example
Of minds disparity
they live with blinders on------we are not all the same!
Kind of like saying, “I’m probably the smartest president ever, maybe nobody is smarter than me.
Possibly nobody knows more about lawsuits than I do, or it is unknown if anybody is better than me at almost anything.
I could be the greatest at everything, that is why I might be the very best ever. We were bigger than Elton John and we didn’t even have instruments.
R.I.P Twisted Anti-Vaxxers Rush to Blame Matthew Perry’s Death on Covid Vaccine
If that weren’t enough, anti-vaxxers edited Perry’s Wikipedia page to say, “It is unclear whether the drowning was due to complications from the COVID-19 vaccine.” (It has since been deleted.)
Vaccines Offer Surprising Protection Against Alzheimer’s- the anti-vaccine community is not going to like this one